Navigation Links
Novavax Reports First Quarter 2008 Financial Results
Date:5/9/2008

ROCKVILLE, Md., May 9 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the first quarter 2008. Novavax reported a net loss of $7.8 million ($0.13 loss per share) for the first quarter of 2008 compared to a net loss of $8.4 million ($0.14 loss per share) for the first quarter of 2007. Total cash and short-term investments as of March 31, 2008 were $40.9 million compared to $46.5 million as of December 31, 2007. The cash burn for the quarter was $5.6 million.

The following are key achievements during the quarter as well as additional plans for the balance of the year:

-- Commenced Phase IIa clinical studies for its H5N1 pandemic influenza

vaccine as a continuation of the original Phase I/IIa trial which

started last year. An interim analysis in December 2007 was favorable,

indicating that this vaccine demonstrated immunogenicity at 15

microgram and 45 microgram dose levels and was well tolerated. The

Company remains on plan to report preliminary immunogenicity results

from the dose-ranging portion of this Phase IIa study in late third

quarter/early fourth quarter of 2008.

-- Continued as planned to advance its seasonal influenza vaccine program

through pre-clinical studies with a target of commencing human trials

in a Phase IIa study in early third quarter of 2008. The Company

believes the initial results from the pandemic influenza vaccine study

bode well for the seasonal program. It is important to note the safety

data generated in the ongoing Phase I/IIa H5N1 pandemic influenza study

will be used to support the safety database for our seasonal program

which will allow us to begin human trials for this program with a Phase

IIa trial.

-- Pending a successful outcome of the Phase IIa trial, an additional

Phase IIb trial of our seasonal infl
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Merck KGaA, Darmstadt, ... and top-quality high-tech products in the healthcare, life science ... US-based company Nano-C, their development and launch of promising ... photovoltaics (OPV). Merck KGaA, Darmstadt, Germany ... growing OPV sector. Novel derivatives: highly stable, ...
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... GERMANTOWN, Md. , Aug. 3, 2015   ... it will release first half and second quarter 2015 ... 10 th , 2015.  The Company will host a ... results and provide a general business update. ... (Domestic US) and 1-412-902-4262 (International), and asking to join ...
(Date:8/3/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a ... autologous cell therapies, announced today that RepliCel,s CEO, David ... in Minneapolis, Minnesota on August 5 ... highlight RepliCel,s 18-month milestones including CE Mark for its RCI-02 ... clinical data from both RCT-01 (tendon) and RCS-01 (skin) clinical ...
Breaking Biology Technology:Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2
... 19, 2012  Nautilus Neurosciences announced today that their ... subsidiary of Stellar Pharmaceuticals, was granted a Notice ... CAMBIA® (diclofenac potassium for oral solution) in the ... in adults. CAMBIA® is expected to be launched ...
... Cancer Research Centre (CNIO) routinely runs such tests on samples ... just the first step towards a truly personalised medicine. And ... in each organism at a molecular scale: the genes that ... antibodies circulating through the bloodstream; and the length of the ...
... of yoghurt have a note telling you that the product ... the spatial arrangement of their atoms. The two"isomers", L(+) and ... light to the right or left respectively. Of course the ... is not confined to solutions of yoghurt. Light interacts in ...
Cached Biology Technology:Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine 2Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine 3CNIO researchers take part in the most comprehensive personalized medicine study performed to date 2CNIO researchers take part in the most comprehensive personalized medicine study performed to date 3Designer lights from the physics lab 2
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... malaria parasites form mutations that make them stubbornly resistant ... new treatments for a disease that afflicts more than ... disease models using yeast and successfully introduced five mutations ... The study, featured as the cover story of the ...
... consequences for humans and most animals but not Australia's ... The University of Queensland has found that unlike most ... starvation, the green-striped burrowing frog is able to absorb ... food, than frogs that had eaten regularly. , "They ...
... community over the evolution of the Great White shark, and ... Wright State University Lake Campus, is right in the middle ... one of the most feared predators of the sea, evolved ... rests with the mako shark. , "Most scientists would probably ...
Cached Biology News:Molecular models advance the fight against malaria 2A frog's life is food for thought 2A frog's life is food for thought 3Great White shark evolution debate involves WSU Lake Campus geology professor 2
Agarose, Biotechnology grade, 500g...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
... The c-Jun proto-oncogene was first identified as ... v-jun oncogene. Jun B and Jun D have ... in their C-terminal regions, which are involved in ... which are involved in transcriptional activation, diverge. ...
...
Biology Products: